Launch of employee health screening service

EDX Medical Group PLC

15 July 2026

15 July 2026

EDX Medical Group plc · EDX

("EDX Medical" or the "Company")

EDX MEDICAL LAUNCHES EMPLOYEE HEALTH AND

WELLBEING SCREENING SERVICE

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for major diseases, announces that it is launching a new health and wellbeing screening service in the UK which features comprehensive tests for employees.

The service will involve general health checks and will also include biomarker testing panels that determine risk of cancer, cardiovascular disease and metabolic disorders.  

The health screening service will comprise a series of comprehensive panels of individual biomarkers.  These panels of tests range from 40 to 80 biomarkers covering more than 100 disease conditions.

Test results are to be computed along with employee health and family history questionnaires to generate an extremely accurate and useful picture of an individual's health status.

EDX Medical has reached agreement in principle with three significant UK employers, which have a total of 14,000 employees, to undertake health screening, subject to final documentation. Testing is expected to commence in Q4 this calendar year.

The Company estimates that, on the basis of the current agreements in principle, fulfilment of these agreements could generate revenue in excess of £2million this financial year, with repeat testing to be carried out in future years.

EDX Medical will deploy its experienced team of nurses and logistics managers to undertake the testing sessions in the workplace and a follow-up service which includes the provision of advanced diagnostic tests if required by an employee.

Professor Sir Chris Evans, OBE, founder of EDX Medical,commented: "We are delighted to announce the launch of a corporate health and wellbeing screening service, and we anticipate strong demand from employers for a service that will help keep their staff healthy. We are very pleased that major employers are immediately supportive of our service and we are in discussion with several other leading UK businesses.

"EDX Medical has developed the testing panels for more than 18 months and designed a unique range of biomarker combinations which we believe offer a superior, comprehensive and price-competitive testing range compared with other diagnostic services available in the UK or Europe. Our tests have regulatory approval, and the biomarker panels are perfectly designed to monitor a comprehensive range of major diseases that could seriously affect the health of employees. It is abundantly clear that early detection of a range of diseases can be transformative for both employee and employer.

"As a diagnostic company with experience of testing in the workplace, it is clear that employee health screening is growing in popularity because it dramatically decreases long-term absenteeism while at the same time improves loyalty from employees who appreciate their health being actively considered by their employer."

An estimated 148.8 million working days were lost because of sickness or injury in 2025, according to the Office of National Statistics, and official estimates state £130 billion is lost annually to the UK economy, driven by lost working capacity, recruitment costs, and decreased output.

For enquiries, please contact:

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	+44 (0)7812 345 301
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews	+44 (0) 20 7523 8318
Media House International
Ramsay Smith Gary McQueen	+44 (0)7788 414856 ramsay@mediahouse.co.uk + 44 (0)7834 694609 gary@mediahouse.co.uk
IFC Advisory (Investor Relations)
Graham Herring Tim Metcalfe	+44 (0) 203 934 6630

About EDX Medical Group plc

The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.